drugset / Trial / NCT02670551

Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression

NCT02670551

Phase 3 Completed 488 enrolled Forest Laboratories
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study investigates the efficacy of a fixed-dose regimen of cariprazine 1.5 milligram (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.

Timeline

Start
2016-03-17
Primary completion
2017-07-19
Completion
2017-07-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 1.5 mg Oral
Subject Cariprazine Small molecule 3 mg Oral